ASH 2023 | Long-term real-world experience of CPX-351 in patients with t-AML and MRC-AML
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, presents the findings of a study which aimed to use long-term follow-up data from the clinical setting to evaluate the efficacy of CPX-351 for treating patients with therapy-related acute myeloid leukemia (t-AML) and AML with myelodysplasia-related changes (MRC-AML). Prolonged overall survival (OS) and high rates of measurable residual disease (MRD)-negativity were observed in patients treated with this drug. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Jazz Pharma, Abbvie, Novartis, Servier, BMS
Speakers Bureau: Jazz Pharma, Abbvie, Novartis, Servier, Incyte, BMS, Keros, Syros
